Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (the TRIUMPH Study)
Latest Information Update: 26 Oct 2023
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms TRIUMPH
- 23 Oct 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.
- 23 Oct 2023 Planned primary completion date changed from 1 Jun 2022 to 1 Dec 2023.
- 23 Oct 2023 Status changed from recruiting to active, no longer recruiting.